Palonosetron+Aprepitant+Dexamethasone for moderately emetic chemotherapy induced nausea and voimiting-Phase II study-

Palonosetron+Aprepitant+Dexamethasone for moderately emetic chemotherapy induced nausea and voimiting-Phase II study- - Palonosetron+Aprepitant+Dexamethasone for moderately emetic chemotherapy induced nausea and voimiting

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004936

Enrollment

160

Registered

2011-01-24

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Aprepitant: 125mg po. 1-1.5 hr. prior to chemotherapy on Day1 Palonosetron:0.75mg iv. prior to chemotherapy on Day1 Dexamethasone: 4.95mg iv. 30 min. prior to chemotherapy on Day 1, 4mg po. on Day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically or cytologically proven Lung cancer 2)Moderately or Highly emetic chemotherapy 3)Patient receiving moderately emetic chemotherapy defined by NCCN guideline 2009, ver 1. 3) Written IC.

Exclusion criteria

Exclusion criteria: 1)MEC administration except Day 1. 2)Radiation therapy 3)Contraindication of Dexamethasone 4)Symptomatic brain meta 5)Hypersensitivity for Palonosetron, Aprepitant, Dexamethasone 6)Vomiting episode prior to chemotherapy with 24 hours

Design outcomes

Primary

Measure	Time frame
Complete response rate in 1st course of chemotherapy	—

Secondary

Measure	Time frame
Complete response rate in any course of chemotherapy Complete control rate Time to treatment failure QOL analysis Toxicity	—

Countries

Japan

Contacts

Public ContactHirohisa Yoshizawa

Niigata University Medical and Dental Hospital Bioscience Medical Research Center

hy0522@med.niigata-u.ac.jp025-227-2517

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026